|
Tuesday, June 28 |
||
|
|
|
|
|
6:00 PM |
|
Conference Registration |
|
|
|
|
|
8:00 PM |
|
Welcome Reception/Dinner |
|
|
|
|
|
Wednesday, June 29 |
||
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
9:00 AM |
|
Welcome and Opening Remarks |
|
|
|
|
|
9:05 AM |
1 |
New milestones ahead in complement-targeted therapy Daniel Ricklin and John Lambris |
|
|
|
|
|
Session I |
|
Antibodies in Autoimmunity, Therapy & Diagnostics Chairs: Sacha Zeerleder and Lubka Roumenina |
|
9:30 AM |
2 |
Amelioration of disease in the MRL/lpr model of lupus by treatment with an Anti-C3d monoclonal antibody that blocks C3d:CR2 ligand: Receptor interactions Liudmila Kulik, Jennifer Laskowski, Joshua Thurman, and Michael Holers |
|
9:55 AM |
3 |
The role of complement component C3aR during vertebrate eye development Erika Grajales-Esquivel, Agustín Luz-Madrigal, Jeff Bierly, Zachary McKinney, Edimara Reis, Apostolia Tzekou, Panagiotis Tsonis, John Lambris, and Katia Del Rio-Tsonis |
|
10:20 AM |
4 |
Automated CH50-like assay for assessment of the complement system Ian Mackie, Chris Gardiner, Phil Lane, Andy Chitolie, Miles Nunn, and Sam Machin |
|
10:35 AM |
5 |
Plasma iC3b is reduced following successful eculizumab treatment in atypical hemolytic uremic syndrome using a rapid lateral flow assay platform Nick Staten, W Schaiff, Robin Bruchas, Shangbin Yang, Haiwa Wu, Haifeng Wu, Paul Olson, Spero Cataland, and Martin Schmidt |
|
10:50 AM |
6 |
Considerations and pitfalls for complement biomarkers in drug development Ashley Frazer-Abel, Jennifer Laskowski, Joshua Thurman, and Patricia Giclas |
|
|
|
|
|
11:05 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
Session II |
|
Targeting the Amplification Loop Chairs: Richard Smith and Mihaly Jozsi |
|
12:00 PM |
7 |
Compstatin Cp40 (AMY-101): a C3-targeted complement inhibitor reaching its prime for bedside intervention John D Lambris, Edimara Reis, Alexandra Primikyri, Yiannis Sarigiannis, Sofia Koutsogiannaki, Malvina Papanastasiou, Hongbin Wang, Markus Huber-Lang, Martijn van Griensven, Bo Nilsson, Kristina Nilsson-Ekdahl, Richard J Smith, Dimitrios Mastellos, Margaret A Lindorfer, Ronald P Taylor, Laura Evgin, John Bell, Gang Chen, Evlambia Hajishengallis, George Hajishengallis, Despina Yancopoulou, Antonio M Risitano, and Daniel Ricklin |
|
12:25 PM |
8 |
Complement immunotherapy using compstatin derivatives Delphine El Mehdi, Federico Grossi, Pascal Deschatelets, and Cedric Francois |
|
12:40 PM |
9 |
The molecular mechanisms underlying regulation of complement activity Piet Gros |
|
1:05 PM |
10 |
Potentiation of natural complement regulators through protein engineering Christoph Schmidt |
|
1:30 PM |
11 |
Antisense therapy targeting complement factor B Tamar Grossman, Robert Johnson, Lijiang Shen, Lisa Hettrick, Michele Carrer, Scott Henry, Brett Monia, and Michael McCaleb |
|
1:45 PM |
12 |
Small-molecule Factor B inhibitors for oral treatment of alternative pathway driven diseases Anna Schubart, Juergen Maibaum, Karen Anderson, Holger Sellner, Aengus MacSweeney, Amanda Littlewood-Evans, Antonio Risitano, Sha-Mei Liao, Finton Sirockin, Eric Valeur, Wolfgang Miltz, Stefan Randl, Bernd Gerhartz, Frederic Cumin, Bruce Jaffee, Richard Harrison, and Joerg Eder |
|
2:00 PM |
13 |
Preclinical evaluation of ACH-4471: A potent, specific and oral complement factor D inhibitor Mingjun Huang, Xuan Yuan, Eleni Gavriilaki, Steven Podos, Jane Thanassi, Guangwei Yang, Andrea Baines, Dharaben Patel, Yongsen Zhao, Joanne Fabrycki, Manuel Galvan, Amanda Luu, Wengang Yang, Yongqing Huang, Avinash Phadke, Jason Wiles, and Robert Brodsky |
|
|
|
|
|
2:15 PM |
|
Lunch/Informal Discussions |
|
|
|
|
|
7:30 PM |
|
Dinner/Informal Discussions at a local Greek Restaurant |
|
The buses for the restaurant will depart from the hotel at 7:30 PM |
||
|
|
|
|
|
Thursday, June 30 |
||
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
Session III |
|
C3 Glomerulopathy and aHUS Chairs: Matthew Pickering and Meryl Waldman |
|
9:00 AM |
14 |
C3G – Insights into a puzzling disease Richard Smith, Yuzhou Zhang, Xue Xiao, Bertha Martin, Lexie Leonhardt, Nicolo Borsa, Fengxiao Bu, and Carla Nester |
|
9:25 AM |
15 |
Understanding complement-mediated renal diseases using protein structure-function relationships Lubka Roumenina, Sophie Chauvet, Maria Chiara Marinozzi, Tania Rybkine, and Veronique Fremeaux- Bacchi |
|
9:50 AM |
16 |
Update on C3 glomerulopathy: role of complement receptor 3 (CR3) Matthew Pickering |
|
10:15 AM |
17 |
Complement as target in C3 glomerulopathy Carla Nester, Yuzhou Zhang, Xue Xiao, Bertha Martin, Lexie Leonhardt, Nicolo Borsa, Fengxiao Bu, and Richard Smith |
|
10:40 AM |
18 |
Properdin as a therapeutic target in the treatment of complement-mediated diseases Wenchao Song, Damodar Gullipalli, Takashi Miwa, Yoshiyasu Ueda, and Sayaka Sato |
|
11:05 AM |
19 |
Functional characterization of a disease-associated N-terminal factor H mutation Marcell Cserhalmi, Barbara Uzonyi, Dorottya Csuka, Edgar Meusburger, Karl Lhotta, Zoltán Prohászka, and Mihály Józsi |
|
|
|
|
|
11:20 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
Session IV |
|
Neurological Diseases, IRI & Transplantation Chairs: Markus Huber-Lang and Sander Connolly |
|
12:00 PM |
20 |
Complement in neurological disease: biology, biomarkers and magic bullets Paul B Morgan |
|
12:25 PM |
21 |
The lectin pathway in acute brain injury Maria-Grazia De Simoni |
|
12:50 PM |
22 |
Human models of cerebral reperfusion injury: Opportunities for development of anti-complement cascade therapies Sander E Connolly |
|
1:15 PM |
23 |
Peptide Inhibitor of Complement C1 (PIC1) improves neurological outcomes in a rat model of neonatal hypoxic-ischemic encephalopathy (HIE) Tushar Shah, Jasmine Nejad, Haree Pallera, Frank Lattanzio, Rawad Farhat, Parvarthi Kumar, Pamela Hair, Kenji Cunnion, and Neel Krishna |
|
1:30 PM |
24 |
Role of Collectin 11 in injury of the newly transplanted kidney Steven Sacks, Conrad Farrar, David Tran, Wilhelm Schwaeble, and Wuding Zhou |
|
1:55 PM |
25 |
TNT009 and its parental mouse monoclonal antibody TNT003 target complement component C1s and effectively block alloantibody-induced classical complement pathway activation Markus Wahrmann, Jakob Mühlbacher, Lena Marinova, Heinz Regele, Nicole Huttary, Farsad Eskandary, James Gilbert, Sandip Panicker, and Georg Böhmig |
|
|
|
|
|
2:10 PM |
|
Lunch/Informal Discussions |
|
|
|
|
|
7:30 PM |
|
Dinner/Informal Discussions at a local Greek Restaurant |
|
The buses for the restaurant will depart from the hotel at 7:30 PM |
||
|
|
|
|
|
Friday, July 1 |
||
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
9:00 AM |
26 |
Funding translational research and development of pharmaceutical innovation – sources and strategies to create novel therapeutics Charles Baltic |
|
|
|
|
|
Session V |
|
PNH and Hematological Disorders Chairs: Ron Taylor and Christoph Schmidt |
|
9:25 AM |
27 |
Complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) Rodrigo Calado |
|
9:50 AM |
28 |
Cross-talking between complement and coagulation in PNH: therapeutic implications Anita Hill |
|
10:15 AM |
29 |
CD59 is critical for the control of C3 activation on erythrocytes surface Michela Sica, Tommaso Rondelli, Patrizia Ricci, Maria De Angioletti, Antonio Risitano, and Rosario Notaro |
|
10:30 AM |
30 |
Therapeutic complement inhibition in PNH: where are we going? Antonio Risitano |
|
10:55 AM |
31 |
Thrombotic microangiopathy after hematopoietic stem cell transplantation Régis Peffault de la Tour |
|
11:20 AM |
32 |
IgM mediated autoimmune hemolytic anemia: the role of complement inhibition Inge Baas, Sacha Zeerleder, and Diana Wouters |
|
|
|
|
|
11:45 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
Session VI |
|
Targeting Complement Initiation & Effectors Chairs: Piet Gros and Suzan Rooijakkers |
|
12:15 PM |
33 |
The novel role of activation of complement cascade in pathogenesis of hematopoietic malignanices and modulatory effect of heme oxygenase-1 (HO-1) Mariusz Ratajczak |
|
12:40 PM |
34 |
The lectin pathway bridges the complement and the contact system in thromboinflammation Bo Nilsson |
|
1:05 PM |
35 |
A monoclonal antibody against complement C2, as a novel complement inhibitor Peter Boross, Cafer Yildiz, Peter Simons, Louis Boon, and C Hack |
|
1:20 PM |
36 |
Structural basis for eculizumab-mediated inhibition of complement C5 Janus Schatz-Jakobsen, Yuchun Zhang, Krista Johnson, Douglas Sheridan, and Gregers Andersen |
|
1:35 PM |
37 |
Discovery of the first functionally selective C5aR2 ligands Daniel Croker, Peter Monk, Reena Halai, Geraldine Kaeslin, Zoe Schofield, Mike Wu, Richard Clark, Mark Blaskovich, Dimitrios Morikis, Christodoulos Floudas, Matthew Cooper, and Trent Woodruff |
|
1:50 PM |
38 |
Complement and Toll-like receptors as targets to treat inflammation: inhibition of C3 or C5 together with CD14 emerges as a promising strategy Andreas Barratt-Due, Søren Pischke, Per Nilsson, Terje Espevik, and Tom Mollnes |
|
|
|
|
|
2:05 PM |
|
Lunch/Informal Discussions |
|
|
|
|
|
3:30 PM |
|
City Tour |
|
The buses for the restaurant will depart from the hotel at 3:30 PM |
||
|
|
|
|
|
7:30 PM |
|
Dinner/Informal Discussions at a local Greek Restaurant Please note buses do not pick-up at the hotel prior to dinner. Dinner proceeds right after the tour. |
|
|
|
|
|
Saturday, July 2 |
||
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
Session VII |
|
Infection, Inflammation & Trauma Chairs: George Hajishengallis and Edimara Reis |
|
9:00 AM |
39 |
Complement reactions on bacteria Suzan Rooijakkers |
|
9:25 AM |
40 |
Unlocking the mysteries of the interplay between malaria and complement Jose Stoute |
|
9:50 AM |
41 |
Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application George Hajishengallis, Tetsuhiro Kajikawa, Evlambia Hajishengallis, Baomei Wang, Edimara Reis, Despina Yancopoulou, Daniel Ricklin, and John Lambris |
|
10:15 AM |
42 |
Complementing the inflammasome Kathy Triantafilou |
|
10:40 AM |
43 |
Protective Effects of Compstatin in Hemorrhagic Shock Markus Huber-Lang, Stephanie Denk, John Lambris, and Martijn van Griensven |
|
11:05 AM |
44 |
Therapeutic inhibition of C3 promotes wound healing Edimara Reis, Sophia Koutsogiannaki, Alexandra Primikyri, Ranillo Resuello, Joel Tuplano, Despina Yancopoulou, Daniel Ricklin, and John Lambris |
|
|
|
|
|
11:20 AM |
|
Coffee Break & Poster Viewing |
|
|
|
|
|
Session VIII |
|
Cancer and Proliferation Chairs: Antonio Risitano and Cecilia Garlanda |
|
11:50 AM |
45 |
Antibodies that efficiently form hexamers upon antigen binding can induce CDC under complement-limiting conditions Ronald Taylor, Erika Cook, Margaret Lindorfer, Frank Beurskens, Hilma van der Horst, Simone Oostindie, Janine Schuurman, Clive Zent, Richard Burack, and Paul Parren |
|
12:15 PM |
46 |
Soluble gC1qR activates the complement and kinin systems in a manner that sustains tumor growth, survival and migration Berhane Ghebrehiwet and Ellinor Peerschke |
|
12:40 PM |
47 |
Role of Complement in murine cancer development and its translational relevance Cecilia Garlanda |
|
1:05 PM |
48 |
Ribosomal protein S 19 suppresses antitumor immune responses via the complement C5a receptor Maciej Markiewski, Magdalena Karbowniczek, Surya Vadrevu, Jun-Hyng Cho, Jalpa Patel, and Bhaumik Patel |
|
1:20 PM |
49 |
Complement C3a receptor: a therapeutic target for primary and metastatic melanoma? Jamileh Nabizadeh, Helga Manthey, Frederik Steyn, Glen Boyle, Stephen Taylor, Trent Woodruff, and Barbara Rolfe |
|
1:35 PM |
50 |
Role of C3a-C3aR axis during intestinal tumorigenesis Silvia Guglietta, Lukas Weber, Carsten Krieg, Bruno Fosso, Graziano Pesole, Giuseppe Penna, Mark Robinson, and Maria Rescigno |
|
1:50 PM |
51 |
Complement-mediated adverse reactions to PEGylated nanocarriers: Role of natural and induced anti-drug antibodies Janos Szebeni, Tamas Mészáros, Rudolf Urbanics, and Gergely Kozma |
|
|
|
|
|
2:15 PM |
|
Closing Remarks |
|
|
|
|
|
2:20 PM |
|
Lunch/Informal Discussions |
|
|
|
|
|
8:00 PM |
|
Farewell Dinner |
|
|
|
|
|
Sunday, July 3 |
||
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
9:00 AM |
|
Departure |
|
Posters |
|
|
52 |
Elucidating the molecular mechanisms of complement-mediated neutrophil phagocytosis Ronald Gorham Jr, Shi You Fu, Fernanda Paganelli, and Suzan Rooijakkers |
|
53 |
Discriminating complement-mediated acute transfusion reaction (ATR) for type O+ erythrocytes transfused into a B+ recipient with the Complement Hemolysis Using Human Erythrocytes (CHUHE) assay Kenji Cunnion, Pamela Hair, Pamela Whitley, Corinne Goldberg, Emmanuel Fadeyi, Lanne Maes, and Neel Krishna |
|
54 |
Improving complement regulation by a potentiating antibody against complement factor H as a new therapeutic strategy Richard Pouw, Mieke Brouwer, Taco Kuijpers, and Diana Wouters |
|
55 |
In vitro evaluation of a novel CRIg-Factor H hybrid complement inhibitor Marcell Cserhalmi, Mario Hebecker, Tam Tamás Mészáros, János Szebeni, and Mihály Józsi |
|
56 |
Complement regulator CTRP6 and inflammatory diseases Masanori Murayama, Kenzo Matsuo, Kaori Yoshida, Nanako Katagiri, and Yoichiro Iwakura |
|
57 |
A novel and pivotal role of the mannose-binding lectin (MBL) pathway of complement cascade (ComC) activation in triggering mobilization of hematopoietic stem/progenitor cells (HSPCs) Mateusz Adamiak, Ahmed Abdel-Latif, Janina Ratajczak, and Mariusz Ratajczak |
|
58 |
The long pentraxin PTX3 and the alternative complement pathway cooperate in the immune response to Aspergillus fumigatus Raffaella Parente, Francesca Petroni, Sonia Valentino, Marina Sironi, Barbara Bottazzi, Alberto Mantovani, and Antonio Inforzato |
|
59 |
Creation of mouse models of complement-mediated renal disease using CRISPR-CAS9 to introduce known human Factor H mutations in human C5a-receptor knock-in mice Chris Li, Israel Charo, Linda Ertl, Pirow Bekker, and Thomas Schall |
|
60 |
Possible tegimes to inhibit cholesterol crystal-induced inflammation in atherogenesis Terje Espevik, Siril Bakke, Nathalie Niyonzima, Marie Aune, Stig Nymo, Eivind Samstad, Liv Ryan, Jan Damås, Bente Halvorsen, Eicke Latz, and Tom Mollnes |
|
61 |
C5L2 and C5aR, the good guys and the bad guys, in arrhythmogenic cardiomyopathy Manolis Mavroidis |
|
62 |
Proliferation of medulloblastoma cells stimulated by tumor necrosis-initiated complement activation Joshua Burks, Robert Briggs, Phillip Bonney, Shweta Agarwal, James Battiste, Kar-Ming Fung, and Michael Sughrue |
|
63 |
The complement system in head and neck squamous cell carcinoma Ulrike Werner, Monir Jalilpour, Franziska Wendt, Ralph Pries, and Barbara Wollenberg |
|
64 |
Safety and effectiveness of restricted eculizumab regimen in atypical HUS Kioa Wijnsma, Elena Volokhina, Lambertus van den Heuvel, Jack Wetzels, and Nicole van de Kar |
|
65 |
Pharmacokinetics and pharmacodynamics of eculizumab in individualized treatment of atypical HUS Elena Volokhina, Kioa Wijnsma, Fred Sweep, Roger Brüggemann, Jack Wetzels, Nicole van de Kar, and Lambertus van den Heuvel |
|
66 |
Glycans of α1-antichymotrypsin impurity in C1-inhibitor therapeutics exhibit antiinflammatory effect attributed to C1-inhibitor Ruchira Engel, Laura Nuñez, Dorina Roem, Gerard van Mierlo, Stephanie Holst, Agnes Ederveen, Jaap van Buul, Manfred Wuhrer, Diana Wouters, and Sacha Zeerleder |
|
67 |
Pediatric C3 glomerulopathy: One center experience Marie-Michèle Gaudreault-Tremblay, Natacha Patey, Arnaud Bonnefoy, Geneviève Benoit, Marie-José Clermont, Aicha Mérouani, Véronique Phan, and Anne-Laure Lapeyraque |
|
68 |
Persistent isolated serum C3 consumption identifies a high-risk subgroup in lupus nephritis (LN) Lucio Manenti, Maria Letizia Urban, and Augusto Vaglio |
|
69 |
Homing strategies which target iC3b promote neurologic recovery after traumatic brain injury in mice Marieta Ruseva, Valeria Ramaglia, Paul Morgan, and Claire Harris |